|
Pre-treatment
serum IgE (IU/mL) |
Body
Weight (kg)
|
|||
|
30-60
|
>60-70
|
>70-90
|
>90-150
|
|
|
>
30-100
|
150
q4 weeks
|
150
q4 weeks
|
150
q4 weeks
|
300
q4 weeks
|
|
>100-200
|
300
q4 weeks
|
300
q4 weeks
|
300
q4 weeks
|
225
q2 weeks
|
|
>200-300
|
300
q4 weeks
|
225
q2 weeks
|
225
q2 weeks
|
300
q2 weeks
|
|
>300-400
|
225
q2 weeks
|
225
q2 weeks
|
225
q2 weeks
|
300
q2 weeks
|
|
>400-500
|
300
q2 weeks
|
300
q2 weeks
|
375
q2 weeks
|
Do
Not Use
|
|
>500-600
|
300
q2 weeks
|
375
q2 weeks
|
Do
Not Use
|
|
|
>600-700
|
375
q2 weeks
|
Do
Not Use
|
||
| q=every Adapted from: Omalizumab package insert. 1 DNA Way, CA:Genentech Inc.; June 2003 |
Click Here to Return to Article